YONKERS, N.Y., May 15 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corp. (OTC Bulletin Board: ADVR) today announced that Mark H. Kaplan, MD, has
joined the Company's Scientific Advisory Board. Dr. Kaplan brings specialized
expertise in AIDS treatment and research, including the study of new
therapeutic agents, to the Scientific Advisory Board.
Dr. Kaplan is the Jane and Dayton Brown Professor of Clinical Medicine at
The New York University School of Medicine and has been Director of The Center
for AIDS Research and Treatment at The North Shore University Hospital since
1994. Dr. Kaplan, a prominent specialist in infectious diseases who now
devotes his attention to problems of AIDS, was previously Chief of Infectious
Diseases at The North Shore University Hospital from 1980 through 1994. He
also had served on the adjunct staff and was guest investigator at Rockefeller
University from 1978 through 1984.
"We are aggressively pursuing the possible use of Product R in the
treatment of HIV infection and AIDS, and we are awaiting approval to begin
clinical studies of Product R in AIDS related wasting (cachexia) and the
possible salvage effects of Product R in these patients. Dr. Kaplan's
expertise will be important in helping to define the promising role of Product
R in the treatment of AIDS," stated Shalom Z. Hirschman, MD, Chief Executive
Officer and President of Advanced Viral Research Corp. "Dr. Kaplan has
conducted many clinical trials in patients with AIDS, including studying the
therapeutic potential of such drugs such as Viracept and new drug combinations
in patients with AIDS, and we look forward to his counsel in the development
of our innovative drug, Product R."
"There is a definite need for new types of therapies to alleviate the
sufferings of patients with AIDS. I am eager to work with the other members
of the Scientific Advisory Board and the scientific staff of Advanced Viral
Research Corp. to help establish the role of Product R in the treatment of
patients with AIDS," said Dr. Kaplan. "Product R represents a new type of
potential therapy for patients with AIDS and should be subjected to rigorous
clinical trials to decipher its role in the treatment of patients with HIV
infection and AIDS. I look forward to the exciting prospect of helping to
advance these scientific investigations."
Dr. Kaplan joins fellow Scientific Advisory Board members Dr. Howard A.
Young, a world-renowned microbiologist and immunologist; Dr. George Canellos
(Harvard Medical School and Dana Farber Cancer Institute); Dr. Michael Harris
(Tomorrows Children's Institute for Cancer and Blood Disorders and UMDNJ-New
Jersey Medical School); Dr. James D'Olimpio (North Shore University Hospital
and New York University School of Medicine); and Ms. Carol Armenti (Center
for Cervical Health). The Company formed the Scientific Advisory Board in
January to bring broad-ranging scientific expertise to the Company's efforts
to develop its flagship drug, Product R.
Product R is being investigated as a non-toxic peptide-nucleic acid-type
immunomodulator that appears to stimulate the proinflammatory responses
required to combat viral infections such as AIDS and human papilloma virus and
to dampen aberrant autoimmune-type inflammatory responses, such as occur in
patients with rheumatoid arthritis. Therefore, Product R has been termed a
"switch type" immunomodulator. Product R is also being studied for the
promise shown in its ability to mitigate the toxic side effects of other
drugs, including those used to treat HIV infection and chemotherapeutic drugs
employed in the treatment of cancers.
Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm dedicated to improving patients' lives by researching,
developing and bringing to market new and effective therapies for viral and
For further information regarding Advanced Viral Research Corp., please
visit our website at http://www.adviral.com.
Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. Product R is not
approved by the U.S. Food and Drug Administration or any comparable agencies
of any other countries. There is no assurance that the Company will be able
to secure the financing necessary to continue and/or complete the clinical
trials of Product R or satisfy certain other conditions relating to clinical
trials including obtaining adequate insurance on terms acceptable to the
Company. The Company undertakes no obligation to update or revise the
information contained in this announcement whether as a result of new
information, future events or circumstances or otherwise.
Mayr Communications, Inc.